Acquisition tailwinds Acquired by Health Network Laboratories in early 2019, signaling consolidation opportunities for CTGT’s molecular diagnostic services and potential upsell of complementary assays or expanded panels to an established buyer with distribution channels.

NGS expansion History of rolling out new or updated NGS panels (notably in 2014 and 2017) indicates readiness to scale genetics offerings; target opportunities include selling expanded panel coverage, custom panels, or bundled testing for inherited connective tissue disorders.

Web portal readiness Recent launch of a patient results web portal suggests a mature digital delivery capability; potential to partner on patient access solutions, telehealth integrations, or data-driven reporting services for clinics and labs.

Small team leverage With a lean employee base, CTGT could benefit from scalable, low-friction partnerships such as managed services, co-development agreements, or white-label diagnostic solutions to accelerate go-to-market with limited internal resources.

Revenue growth potential Current revenue under one million indicates significant room for expansion via enterprise deals with larger labs, hospital networks, or reference laboratories seeking specialized genetic panels and rapid turnaround capabilities.